RxDoctor Payments Data

Kirsten Bracht, MD

Neurology · Englewood, CONPI 1417940453

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Harmony Biosciences LLC at 38.6% of the total. Among neurology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$150,855in general payments, 2019–2025

Across 271 payments — averaging $556.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$58K
  • Axsome Therapeutics, Inc.$51K
  • Eisai Inc.$25K
  • Jazz Pharmaceuticals Inc.$13K
  • SK Life Science, Inc.$825
  • AbbVie$635
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$61,55041%
  • Speaking & faculty fees$77,05251%
  • Travel & lodging$6,6334%
  • Food & beverage$5,4934%
  • Education$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$150,855 in reported general payments places this provider in the 90th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$82,932
Medicare patients
276
Services billed
3,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate35$669,111
WakixPitolisant Hcl21$196,092
XcopriCenobamate34$61,678
AptiomEslicarbazepine Acetate18$59,235
BriviactBrivaracetam19$38,948
ZonegranZonisamide12$32,870
FycompaPerampanel17$31,091
KeppraLevetiracetam17$24,258
LamictalLamotrigine12$23,304
VimpatLacosamide15$18,455
Clobazam39$13,209
Modafinil20$11,877
Lacosamide57$8,770
Levetiracetam60$7,225
Pregabalin14$4,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$58,231$196,09221 claims
SK Life Science, Inc.Xcopri$825$61,67834 claims
UCB, Inc.Briviact, Vimpat$291$57,40334 claims
Eisai Inc.Fycompa$25,477$31,09117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 neurology providers in Colorado.

Other neurology in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →